
Verve names second PCSK9 candidate; Exscientia picks another AI-created molecule for clinic
Boston-based Verve Therapeutics has unveiled its second PCSK9-targeting program.
The biotech announced the candidate, dubbed Verve-102, as part of its wider third-quarter financial results. Verve’s second PCSK9-targeting candidate is an in vivo drug that uses base editing and is delivered through the company’s own technology known as GalNAc-LNP.
The biotech started the regulatory submission for the program earlier this year and plans to start a Phase Ib trial to treat patients with the genetic disorder heterozygous familial hypercholesterolemia, or HeFH.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.